Sugi Predict

Sugi Predict / Compounds / SCHEMBL18214004

SCHEMBL18214004

SCHEMBL18214004

COC1[C@H](O[C@@H]2C(CO)O[C@@H](O[C@@H]3C(O)[C@H](O[C@@H]4C(CO)O[C@@H](O[C@@H]5C(O)[C@H](C)OC(CO)[C@H]5O)C(O)[C@H]4O)OC(CO[C@@H]4OC(CO)[C@H](O)[C@H](O)C4O)[C@@H]3O)C(NC(C)=O)[C@H]2O)OC(CO)[C@H](O)[C@@H]1O[C@]1(C(=O)O)C[C@@H](O)[C@@H](C)C(C(O)C(O)CO)O1

nearest known ligand 0.59

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
▸ SIGLEC7 Q9Y286 6/20 0.56
▸ SELP P16109 2/20 0.54
▸ SELL P14151 1/20 0.54
▸ SELE P16581 5/20 0.52
▸ MAG P20916 6/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20129887 0.99 SIGLEC7 (0.56) SIGLEC7SELPSELLSELEMAG
SCHEMBL27398460 0.96 SIGLEC7 (0.61) SIGLEC7SELPSELLSELEMAG
SCHEMBL17754964 0.95 SIGLEC7 (0.58) SIGLEC7SELPSELLSELEMAG
SCHEMBL17461351 0.94 SIGLEC7 (0.58) SIGLEC7SELPSELLSELEMAG
SCHEMBL18213995 0.91 SELP (0.57) SIGLEC7SELPSELLSELEMAG
SCHEMBL18214007 0.91 SIGLEC7 (0.59) SIGLEC7SELPSELLSELEMAG
SCHEMBL17827374 0.90 SIGLEC7 (0.57) SIGLEC7SELPSELLSELEMAG
SCHEMBL12451190 0.90 SIGLEC7 (0.57) SIGLEC7SELPSELLSELEMAG
SCHEMBL10038947 0.90 SIGLEC7 (0.61) SIGLEC7SELPSELLSELEMAG
SCHEMBL18365054 0.90 SIGLEC7 (0.61) SIGLEC7SELPSELLSELEMAG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230346903-A1 GROUP B STREPTOCOCCUS POLYSACCHARIDE-PROTEIN CONJUGATES, METHODS FOR PRODUCING CONJUGATES, IMMUNOGENIC COMPOSITIONS COMPRISING CONJUGATES, AND USES THEREOF PFIZER INC. (US) 2023-11-02 — — US disclosed
US-20160324950-A1 GROUP B STREPTOCOCCUS POLYSACCHARIDE-PROTEIN CONJUGATES, METHODS FOR PRODUCING CONJUGATES, IMMUNOGENIC COMPOSITIONS COMPRISING CONJUGATES, AND USES THEREOF PFIZER INC. 2016-11-10 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160324950-A1 GROUP B STREPTOCOCCUS POLYSACCHARIDE-PROTEIN CONJUGATES, METHODS FOR PRODUCING CONJUGATES, IMMUNOGENIC COMPOSITIONS COMPRISING CONJUGATES, AND USES THEREOF SIGLEC7, SIGLEC9, FCGR3B SIGLEC7 1/4885SELP 160/4885SELL 366/4885
US-20230346903-A1 GROUP B STREPTOCOCCUS POLYSACCHARIDE-PROTEIN CONJUGATES, METHODS FOR PRODUCING CONJUGATES, IMMUNOGENIC COMPOSITIONS COMPRISING CONJUGATES, AND USES THEREOF SIGLEC7, SIGLEC9, FCGR3B SIGLEC7 1/4885SELP 160/4885SELL 366/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback